Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cooper Gains Mityvac Vacuum-Assisted Delivery Offering Via Prism Purchase

This article was originally published in The Gray Sheet

Executive Summary

Cooper Companies' CooperSurgical women's healthcare unit will add vacuum-assisted delivery (VAD) to its obstetrics franchise through the $23 mil. purchase of Prism Enterprises

You may also be interested in...



Vacuum-Assisted Delivery Safety Affirmed By Study Data, Panel Review

The majority of serious fetal injuries and fatalities associated with a vaginal-assisted delivery device procedure occurred before the device was applied or resulted from physician urgency or error, according to an FDA-sponsored study

CooperSurgical

Womens healthcare product line acquired Jan. 31 from German company Leisegang Medical for $10.5 mil. includes colposcopes, loop electrosurgical excision instruments, gynecological and cyrosurgical instruments and the Sani-Spec disposable plastic specula. The products generate over $11 mil. in annual sales, and the purchase is expected to be accretive to CooperSurgical (CSI) parent Cooper Companies' fiscal 2000 earnings. CSI's annual revenues are expected to top $50 mil. with the new addition

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel